Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease

Background: Several studies have shown that high plasma lipoprotein(a) concentrations are associated with an increased risk of arteriosclerotic cardiovascular disease. Thus, Lp(a) has emerged as a new therapeutic target. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Seung Woo, Kim, Joan, Jang, Gyeong Won, Lee, Young Shin, Park, Jin Sun, Lee, Jung Myung, Kim, Hyung Oh, Chung, Hyemoon, Woo, Jong Shin, Kim, Woo Shik, Kim, Weon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028952/
https://www.ncbi.nlm.nih.gov/pubmed/35448076
http://dx.doi.org/10.3390/jcdd9040101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028952/
https://www.ncbi.nlm.nih.gov/pubmed/35448076
http://dx.doi.org/10.3390/jcdd9040101

Ejemplares similares